A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

2019-04-18 12:14:32 | BioPortfolio

Published on BioPortfolio: 2019-04-18T12:14:32-0400

Clinical Trials [266 Associated Clinical Trials listed on BioPortfolio]

Predictable MR Index for Nonalcoholic Steatohepatitis (NASH)

1. To evaluate feasibility of using multiparametric Magnetic resonance(MR) imaging to predict nonalcoholic steatohepatitis(NASH) 2. To develop non-invasive diagnosis tool using mul...

Pentoxifylline in Patients With Nonalcoholic Steatohepatitis

One third of the population in the United States has nonalcoholic fatty liver disease (NAFLD). Nonalcoholic steatohepatitis (NASH), the progressive form of NAFLD, can lead to cirrhosis.Cur...

A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH)

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Activity of Seladelpar in Subjects with Nonalcoholic Steatohepatitis (NASH)

Study Evaluating the Safety, Efficacy, and Pharmacokinetics of CORT118335 in Patients With Probable Nonalcoholic Steatohepatitis (NASH)

This phase 2, double blind, placebo-controlled, randomized study is to access the safety and efficacy of CORT118335 in Patients with Probable Nonalcoholic Steatohepatitis (NASH).

A Nonabsorbable Ileal Apical Sodium-Dependent Bile Acid Transporter Inhibitor for Nonalcoholic Steatohepatitis

The objective is to determine whether 24 weeks of treatment with A4250 will improve several clinically-relevant features of NASH compared to treatment with placebo.

PubMed Articles [1162 Associated PubMed Articles listed on BioPortfolio]

NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients with Nonalcoholic Steatohepatitis.

NGM282, an engineered FGF19 analogue, rapidly and significantly reduced liver fat content in a multi-center, randomized, double-blind, placebo-controlled study in patients with biopsy-confirmed nonalc...

Factors Associated with Histologic Response in Adult Patients with Nonalcoholic Steatohepatitis.

Nonalcoholic steatohepatitis (NASH) is a leading cause of liver transplantation and many trials are underway to evaluate potential therapies. The farnesoid X receptor ligand obeticholic acid in NASH t...

Antifibrotic Effects of 1,25(OH)D on Nonalcoholic Steatohepatitis in Female Mice.

Postmenopausal women have a higher risk of nonalcoholic steatohepatitis (NASH) along with an increase in age, and vitamin D deficiency occurs in some patients with NASH.

Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.

Nonalcoholic steatohepatitis (NASH) afflicts 20-36% of individuals with nonalcoholic fatty liver disease (NAFLD). A lipotoxic hepatic environment, altered innate immune signaling and inflammation are ...

New aspects of nonalcoholic steatohepatitis.

During the past 10 years nonalcoholic fatty liver disease (NAFLD) has moved more and more into the focus of attention of clinical research. The term NAFLD comprises the simple nonalcoholic steatosis o...

Medical and Biotech [MESH] Definitions

Cytoplasmic hyaline inclusions in HEPATOCYTES. They are associated with ALCOHOLIC STEATOHEPATITIS and non-alcoholic STEATOHEPATITIS, but are also present in benign and malignant hepatocellular neoplasms, and metabolic, toxic, and chronic cholestatic LIVER DISEASES.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

An effect usually, but not necessarily, beneficial that is attributable to an expectation that the regimen will have an effect, i.e., the effect is due to the power of suggestion.

More From BioPortfolio on "A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)"

Quick Search


Searches Linking to this Trial